(Q34722272)

4 August 2017

1 reference

title

New trial designs to assess antitumor and antiproliferative agents in prostate cancer (English)

1 reference

4 August 2017

1 reference

Walter Stadler

1

1 reference

4 August 2017

1 May 2002

1 reference

Investigational New Drugs

4 August 2017

1 reference

4 August 2017

20

1 reference

4 August 2017

201-208

1 reference

4 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1015618108456

4 August 2017

0 references

cites work

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer

1 reference

12 December 2020

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer

1 reference

12 December 2020

1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy

1 reference

12 December 2020

Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer

1 reference

12 December 2020

Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

1 reference

12 December 2020

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

12 December 2020

A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

1 reference

12 December 2020

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells

1 reference

12 December 2020

Identification and characterization of circulating prostate carcinoma cells

1 reference

12 December 2020

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

12 December 2020

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

1 reference

12 December 2020

Development of target-based antineoplastic agents

1 reference

12 December 2020

Randomized discontinuation trials: Utility and efficiency

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1015618108456

1 reference

PubMed ID

12099580

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

12099580